Arvinas Reports Third-Quarter 2026 Results and Starts ARV-6723 Trial Dosing
Arvinas says it initiated dosing in a Phase 1/2 trial of ARV-6723, an oral immuno-oncology PROTAC. The supplied body is truncated and provides no financial figures.
Related stories
Western Investment Company Raises $55.9M in Private Placement
Western issued 55,865,500 shares at $1.00 each, raising gross proceeds of $55.9 million. Net proceeds are expected to fund its previously announced Canadian Farm and Stockmens acqu
M impact | EQUITY | Nov 03, 2026, 04:37 PM UTC
Kolte-Patil Returns to Profit as Q2 Revenue More Than Doubles
Kolte-Patil Developers reported consolidated net profit of ₹5.3 crore for FY27’s second quarter, versus a net loss of ₹10.4 crore a year earlier. Revenue more than doubled year on
M impact | EQUITY | Nov 03, 2026, 04:36 PM UTC
Kimco Realty Acquires Two Shopping Centers in Louisville
M impact | EQUITY | Nov 03, 2026, 04:35 PM UTC
SOPHiA GENETICS Reports Q3 2026 Revenue Growth and Reaffirms Outlook
Revenue rose 25% year over year to $24.3 million. The company expects 2026 revenue at the upper end of its $94 million to $96 million guidance range.
M impact | EQUITY | Nov 03, 2026, 04:33 PM UTC
Opera Reports Q3 Revenue of $182.8 Million, Adjusted EBITDA of $43.2 Million
Opera said revenue rose 20% year over year to $182.8 million, at the top of its $181–183 million guidance range. Adjusted EBITDA was $43.2 million, above its $41–43 million guidanc
M impact | EQUITY | Nov 03, 2026, 04:33 PM UTC
ChemoMetec Raises 2026/27 Guidance, Reports Preliminary Q1 Results
ChemoMetec lifted revenue guidance to DKK 570–605 million from DKK 560–590 million and EBITDA guidance to DKK 335–360 million from DKK 330–345 million. Preliminary Q1 revenue rose
M impact | EQUITY | Nov 03, 2026, 04:33 PM UTC